Australia markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
7.89+0.37 (+4.92%)
At close: 04:00PM EDT
7.79 -0.10 (-1.27%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.52
Bid7.79 x 21500
Ask7.90 x 27000
Day's range7.42 - 7.91
52-week range7.23 - 10.50
Avg. volume10,012,861
Market cap8.761B
Beta (5Y monthly)1.18
PE ratio (TTM)N/A
EPS (TTM)-0.56
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est10.11
  • Business Wire

    Teva Announces Appointment of New Global R&D and Chief Medical Officer

    TEL AVIV, Israel, July 01, 2022--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the appointment of Eric A. Hughes, MD, PhD as Executive Vice President, Global R&D and Chief Medical Officer. Dr. Hughes will begin his employment on August 1, 2022, and will be based out of Teva's U.S. headquarters in Parsippany, NJ.

  • Business Wire

    Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 2022

    TEL AVIV, Israel, June 29, 2022--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2022 financial results on Wednesday, July 27, 2022 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

  • Motley Fool

    2 Buffett Stocks That Outperformed the S&P During the Great Recession

    There are two things that Teva Pharmaceutical Industries (NYSE: TEVA) and Amazon (NASDAQ: AMZN) have in common. While the index fell by 38% during that time, the healthcare company climbed 10% in value, and the tech giant's 8% decline was modest by comparison. Teva provides patients with generic medications that are much cheaper than brand-name drugs.